Advantages and Limitations of Current Biomarker Research: From Experimental Research to Clinical Application

被引:25
作者
Kim, Seung-Hyun [1 ]
Weiss, Christel [2 ]
Hoffmann, Ursula [1 ]
Borggrefe, Martin [1 ]
Akin, Ibrahim [1 ]
Behnes, Michael [1 ]
机构
[1] Heidelberg Univ, Fac Med Mannheim, Univ Med Ctr Mannheim UMM, Dept Med 1, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany
[2] Heidelberg Univ, Fac Med Mannheim, Univ Med Ctr Mannheim UMM, Dept Stat Anal, Mannheim, Germany
关键词
Cardiovascular disease; heart failure; acute coronary syndrome; biomarker; proteome; metabolome; micro-RNA; ACUTE CORONARY SYNDROMES; ACUTE HEART-FAILURE; C-REACTIVE PROTEIN; CARDIAC RESYNCHRONIZATION THERAPY; BRAIN NATRIURETIC PEPTIDE; LEFT-VENTRICULAR FUNCTION; SENSITIVITY TROPONIN-T; CIRCULATING MICRORNAS; PROGNOSTIC VALUE; RISK STRATIFICATION;
D O I
10.2174/1389201018666170601091205
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Biomarkers are indispensable tools for screening, diagnosis, and prognosis in cardiovascular diseases and their clinical application increases steadily. As cardiovascular diseases include various pathophysiological processes, no single biomarker, even natriuretic peptides, can be regarded as ideal fulfilling all necessary criteria for a comprehensive diagnostic or prognostic assessment revealing optimal clinical application. Hence, multi-marker approaches using different biomarkers reflecting different pathophysiologies were highlighted recently. Advances in biomedical technologies expanded the spectrum of novel blood-derived biomarkers, such as micro-RNA (miRNA) or "omics"data potentially providing a more advanced knowledge about pathogenesis of cardiovascular disease. Conclusion: This review describes the advantages and limitations of blood circulating biomarkers with regard to proteins, metabolomics and transcriptional level both within single as well as multi-marker strategies. Moreover, their usefulness is focused on clinical decision-making in cardiovascular diseases.
引用
收藏
页码:445 / 455
页数:11
相关论文
共 125 条
[21]   Circulating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in Cardiovascular Disease [J].
Corsten, Maarten F. ;
Dennert, Robert ;
Jochems, Sylvia ;
Kuznetsova, Tatiana ;
Devaux, Yvan ;
Hofstra, Leon ;
Wagner, Daniel R. ;
Staessen, Jan A. ;
Heymans, Stephane ;
Schroen, Blanche .
CIRCULATION-CARDIOVASCULAR GENETICS, 2010, 3 (06) :499-506
[22]   Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure [J].
de Antonio, Marta ;
Lupon, Josep ;
Galan, Amparo ;
Vila, Joan ;
Urrutia, Agustin ;
Bayes-Genis, Antoni .
AMERICAN HEART JOURNAL, 2012, 163 (05) :821-828
[23]   The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes [J].
de Lemos, JA ;
Morrow, DA ;
Bentley, JH ;
Omland, T ;
Sabatine, MS ;
McCabe, CH ;
Hall, C ;
Cannon, CP ;
Braunwald, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (14) :1014-1021
[24]   Transcoronary Concentration Gradients of Circulating MicroRNAs [J].
De Rosa, Salvatore ;
Fichtlscherer, Stephan ;
Lehmann, Ralf ;
Assmus, Birgit ;
Dimmeler, Stefanie ;
Zeiher, Andreas M. .
CIRCULATION, 2011, 124 (18) :1936-1944
[25]   B-Type Natriuretic Peptides and Cardiovascular Risk Systematic Review and Meta-Analysis of 40 Prospective Studies [J].
Di Angelantonio, Emanuele ;
Chowdhury, Rajiv ;
Sarwar, Nadeem ;
Ray, Kausik K. ;
Gobin, Reeta ;
Saleheen, Danish ;
Thompson, Alexander ;
Gudnason, Vilmundur ;
Sattar, Naveed ;
Danesh, John .
CIRCULATION, 2009, 120 (22) :2177-U39
[26]   Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy [J].
Di Napoli, P ;
Taccardi, AA ;
Barsotti, A .
HEART, 2005, 91 (02) :161-165
[27]   Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure [J].
Dickinson, Brent A. ;
Semus, Hillary M. ;
Montgomery, Rusty L. ;
Stack, Christianna ;
Latimer, Paul A. ;
Lewton, Steven M. ;
Lynch, Joshua M. ;
Hullinger, Thomas G. ;
Seto, Anita G. ;
van Rooij, Eva .
EUROPEAN JOURNAL OF HEART FAILURE, 2013, 15 (06) :650-659
[28]   Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry [J].
Dunn, Warwick B. ;
Broadhurst, David ;
Begley, Paul ;
Zelena, Eva ;
Francis-McIntyre, Sue ;
Anderson, Nadine ;
Brown, Marie ;
Knowles, Joshau D. ;
Halsall, Antony ;
Haselden, John N. ;
Nicholls, Andrew W. ;
Wilson, Ian D. ;
Kell, Douglas B. ;
Goodacre, Royston .
NATURE PROTOCOLS, 2011, 6 (07) :1060-1083
[29]   Metabolic fingerprinting as a diagnostic tool [J].
Ellis, David I. ;
Dunn, Warwick B. ;
Griffin, Julian L. ;
Allwood, J. William ;
Goodacre, Royston .
PHARMACOGENOMICS, 2007, 8 (09) :1243-1266
[30]   Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients [J].
Ellis, Katrina L. ;
Cameron, Vicky A. ;
Troughton, Richard W. ;
Frampton, Chris M. ;
Ellmers, Leigh J. ;
Richards, A. Mark .
EUROPEAN JOURNAL OF HEART FAILURE, 2013, 15 (10) :1138-1147